Skip to content
Screener

Pacira BioSciences, Inc. PCRX Business Segments — Total other (expense) income, net

Similar metrics at other companies

Forgent Power Solutions logo
FPSReportable Segment — Total Other Expense, net
-$10.46M+13.3%
ImmunityBio, Inc. logo
IBRXReportable Segment — Total other expense, net
-$563M-760%
Lumen Technologies logo
LUMNReportable Segment — Total other expense, net
-$425M-20.7%
Celsius Holdings, Inc. logo
CELHReportable Segment — Other (expense) income, net
-$5.73M+57.6%
Vaxcyte, Inc. logo
PCVXReportable Segment — Total other income, net
$25.23M-37.0%
Crinetics Pharmaceuticals logo
CRNXReportable Segment — Total other income, net
$12.53M-14.3%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$997.34M-11.9%
Enterprise value$1.26B+6.9%
P/E194.1×
P/S1.4×-0.2×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%
Net margin0.7%
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028871
Line itemThree Months Ended March 31, 20262025
Changes in the fair value of contingent consideration(2,277)(2,675)
Legal settlement7,000
Other (2)8801,862
Total operating expenses170,474166,933
Total other (expense) income, net(1,904)6,716
Income before income taxes4,9988,706
Income tax expense(2,082)(3,894)
Net income$2,916$4,812

Item 1. FINANCIAL STATEMENTS (Unaudited)

FAQ

What is Pacira BioSciences, Inc.'s business segments — total other (expense) income, net?
Pacira BioSciences, Inc. (PCRX) reported business segments — total other (expense) income, net of -$1.9M in Q1 2026.
How has Pacira BioSciences, Inc.'s business segments — total other (expense) income, net changed year-over-year?
Pacira BioSciences, Inc.'s business segments — total other (expense) income, net decreased by 128.4% year-over-year, from $6.72M to -$1.9M.
What is the long-term trend for Pacira BioSciences, Inc.'s business segments — total other (expense) income, net?
Over 2 years (2022 to 2024), Pacira BioSciences, Inc.'s business segments — total other (expense) income, net has grown at a -53.1% compound annual growth rate (CAGR), from -$46.72M to $10.27M.
What does business segments — total other (expense) income, net mean?
This metric captures the net impact of non-operating financial activities, such as interest income, interest expense, and gains or losses on debt extinguishment. It reflects the segment's financial management outside of core operational revenue generation. A positive value indicates net non-operating income, while a negative value indicates a net expense.

Ask your AI about Pacira BioSciences, Inc.'s business segments — total other (expense) income, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude